title: [Comparison of visual acuity and central macular thickness after vitrectomy for diffuse diabetic macular edema with or without preoperative treatments].
abstract: OBJECTIVE
  To compare the surgical outcomes during pars plana vitrectomy (PPV) for diffuse diabetic macular edema (DME) with pretreatment to those without pretreatment.
  
  
  METHODS
  The medical charts of 43 eyes of 46 patients who underwent PPV for DME were reviewed. The previously treated (Prev. Tx) group included 19 eyes of 20 patients who were pretreated with intravitreal bevacizumab, sub-Tenon injection of triamcinolone acetonide, and/or subthreshold micropulse diode laser photocoagulation before the PPV. The treatment naïve (Tx.Naïve) group included 24 eyes of 26 patients who underwent PPV alone. The central macular thickness (CMT) and best-corrected visual acuity (BCVA) were measured before treatment and 1, 3, and 6 months after.
  
  
  RESULTS
  In both groups, BCVA at 3 and 6 months and CMT at 1 month or later were significantly better than preoperative visual acuity. CMT at 1 month or later significantly decreased from the preoperative value (p<0.05). The differences in the BCVA and CMT between the Prev. Tx and Tx.Naïve group were not significant.
  
  
  CONCLUSIONS
  PPV either with or without preoperative treatments can significantly improve the BCVA and reduce the CMT in patients with diffuse DME.
authors.affiliation: Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine. t-nizawa@chiba-u.jp
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Nizawa
authors.affiliation: Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine.
authors.forename: Miyuki
authors.initials: M
authors.lastname: Arai
authors.affiliation: Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine.
authors.forename: Yoko
authors.initials: Y
authors.lastname: Takatsuna
authors.affiliation: Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine.
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Oshitari
authors.affiliation: Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine.
authors.forename: Eiju
authors.initials: E
authors.lastname: Sato
authors.affiliation: Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine.
authors.forename: Shuichi
authors.initials: S
authors.lastname: Yamamoto
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000068258:Bevacizumab; D048909:Diabetes Complications / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology / Q000601:surgery*; D005260:Female; D006801:Humans; D056965:Injections, Intraocular; D058449:Intravitreal Injections; D054023:Lasers, Semiconductor / Q000627:therapeutic use; D008028:Light Coagulation; D008266:Macula Lutea / Q000473:pathology*; D008269:Macular Edema / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011300:Preoperative Care; D012189:Retrospective Studies; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000008:administration & dosage; D014792:Visual Acuity; D014821:Vitrectomy
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide